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Precision of robot assisted surgery
superior to conventional surgery
Researchers from Imperial College London have
demonstrated that robot assisted surgery is signif-
icantly more accurate than conventional surgery.
Acrobat, the robotic assistant, was shown to accu-
rately align replacement knee parts with existing
bones, in this prospective randomised controlled
trial led by Professor Cobb. Twenty-seven patients
undertook unicompartmental knee arthroplasty,
13 of which were conventional procedures. In
40% of conventional cases, alignment was achieved
within two degrees of the planned position versus
the 100% success rate of robotic assisted surgery.
Swift recovery and a reduction in complications
were demonstrated, although it was found to be
more time-consuming. Professor Cobb told the
IJS: ‘‘These robots are designed to hold the sur-
geon’s hand in the operating theatre, not take
over the operation. This study shows they can be
an enormous help, preventing surgeons from mak-
ing mistakes. More importantly, by showing how
the increased accuracy makes a difference to
how well a knee works after surgery, we will be
able to develop a new generation of less invasive
procedures without the risks of error, providing
faster recovery and better functional outcomes
for patients. This study could have important im-
plications for not just surgery, but also for health
economics. By improving the accuracy of surgery,
and ultimately improving the outcome for pa-
tients, we can make sure the knee replacements
work better and last longer, preventing the need
for additional surgery.’’
Cobb J et al. Hands on robotic unicompartmen-
tal knee replacement. A prospective randomised
controlled clinical investigation of the Acrobat
system. Journal of Bone and Joint Surgery
2006;88(2):188e197.1743-9191/$ - see front matter
doi:10.1016/j.ijsu.2006.04.009Warning of ambiguous drug trial rights
Compensation following accidental harm to volun-
teers participating in clinical trials could be
a premise due to poorly worded contracts. Patients
are informed of the full risks according to the
government which evaluates contracts whilst the
decision to pay for injuries remains at the discre-
tion of sponsors, according to Professor Laurence
at the University of London. As patients are doing
society a service they deserve to have consumer
contracts fully explained to them in a fair and
open manner which upholds consumer law. Failure
to write documents to be unequivocally under-
stood by lay people could result in serious injury
without guaranteed compensation. This knowl-
edge would clearly impact on the number of
volunteers for trials, but Professor Laurence sug-
gests the solution lies in ‘‘more humane compen-
sation.’’ A department of Health spokesperson
said: ‘‘We do not agree with Professor Laurence
that patients are being misled. People take part in
clinical trials with consent, after seeing informa-
tion about the risks.’’ Louise Hunt, a Partner at
Alexander Harris Solicitors told the IJS: ‘‘This
sounds like it is very confusing for patients, I think
they should be entitled to compensation.’’
Laurence DR. Compensation for non-negligent
harm in trials remains shaky. BMJ 2006;
32(7539):489e490.
International embryonic stem cell
consortium established
The Hinxton Group, an international consortium on
stem cell ethics and law, has been established
following a conference in Cambridgeshire, UK.
Global collaboration is the goal of delegates
from 14 countries which included scientists,
98 Newsphilosophers, bioethicists, lawyers, clinicians and
journal editors. Recommendations for a world-
wide ethical standard in embryonic stem cell
research followed a consensus of slow progress
due to a global discrepancy in policy. It will also
avoid scandals such as the recent South Korean
stem cell research fabrication of Dr Hwang Woo-suk.
The proposal of the new ethical code includes
details of:
 Encouraging journals to request statements
from researchers affirming that their research
complies with their national policy.
 Pooling of research codes and ethical protocols
on an international web-site.
 Striving for ethical consensus, particularly for
new research areas such as human-animal
chimeras.
Professor Julia Savelsecu, ethicist at Oxford
University told the IJS: ‘‘Some countries have
restrictive legislation like Germany, and there
are some with very vague policies like China. In
essence, articulating ethical standards will enable
scientists to collaborate internationally.’’
Cloning research proposal for altruistic
egg donors
Scientists would like women to donate eggs for
the purpose of research as egg donation is
currently permissible for infertile couples hoping
to conceive. Researchers are restricted to asking
women undertaking fertility treatment to donate
surplus eggs that they will not need. Altruistic
donation is currently being debated at the UK’s
Human Fertilisation and Embryology Authority
(HFEA). Despite the shortage of eggs, donation
faces criticism of being an unethical, unnecessary
and invasive option. The donation process itself
can cause fertility problems for the donors and is
thus recommended for those who have already
completed their families. There is also a risk of
a potentially fatal ovarian hyperstimulation syn-
drome, which may cause significant renal dam-
age. Michael O’Sullivan of the pro-life charity Life
told the IJS: ‘‘It is disgraceful that the HFEA is to
entice women to undergo invasive and risky
operations in order to facilitate experimental
research that offers no immediate hope of
cures.’’
A spokesperson for the HFEA has said that it
would need to evaluate this closely as a responsible
regulator.Breast cancer combination therapy
A combination of Taxol (Paclitaxel) and Avastin
(Bevacizumab) extends disease free time in
women with advanced breast cancer and possibly
early breast cancer according to Dr Robin Zon at
the European Breast Cancer Conference in France.
Taxol the chemotherapeutic agent differs from
Avastin, which is a monoclonal antibody providing
anti-angiogenic therapy. The latter is traditionally
used in the treatment of metastatic colorectal
cancer in conjunction with 5-fluorouracil. Only 20%
of women with advanced HER-2 positive tumours
can benefit from Herceptin. The prospect of new
combination therapy therefore provides hope
without the risk of added side effects. A study of
722 women with advanced breast cancer provided
those on combination therapy with 12 months of
no disease progression compared to 7 months for
those treated with chemotherapy alone. The Na-
tional Institute for Health and Clinical Excellence
is appraising this option for widespread NHS use.
Mr Hughes, Chief Executive of Breakthrough Breast
Cancer told the IJS: ‘‘This provides highly encour-
aging news for women with secondary breast
cancer as it could increase the treatment options
available to them. However, the analysis of these
results is only preliminary and the trial needs to
be completed in order to establish the long term
effectiveness and side effects of this combination
of drugs.’’
5th European Breast Cancer Conference (EBCC),
21e25 March 2006, hosted by the European Orga-
nisation for the Research and Treatment of Cancer
(EORTC), The European Breast Cancer Coalition
(EUROPA DONNA) and European Society of Mastol-
ogy (EUSOMA).
Genetic screening test for breast
cancer in the USA
Research led by Mary-Claire King at the University
of Washington, analysed DNA from 300 US patients
with the current genetic screening test for the
BRCA-1, BRCA-2, CHEK2, TP53 and PTEN gene
mutations and have shown a 12% false negative
result. This is due to 12% carrying undetectable
large genomic deletions. Participants were from
high-risk families with negative (wild-type) com-
mercial genetic results for BRCA-1 and BRCA-2.
This test became commercially available in the
mid-1990s as approximately 10% of breast cancers
in the US are due to BRCA-1 and BRCA-2 mutations.
More effective tests are required, there is no
News 99technical error in the current short-range poly-
merase chain reaction (PCR) followed by genomic
sequencing. Whilst small changes are well de-
tected, large deletions are more appropriately
identified with multiplex ligation-dependent probe
amplification (MLDPA). This genetic screening test
is available in Europe but not the US, Mary-Claire
King told the IJS: ‘‘A competitive marketplace is
needed. Inappropriate patent rules stifle the de-
velopment of genetic screening methods in the
US.’’
King MC et al. Spectrum of mutations in BRCA1,
BRCA2, CHEK2, and TP53 in families at high risk of
breast cancer. JAMA 2006;295(12):1379e1388.
Prostate cancer relapse governed
by surgical skill
The surgical skill of the operating surgeon influ-
ences prostate cancer recurrence, alongside the
traditional prognostic features of a neoplasm.
Dr Scardino of the Memorial Sloan-Kettering Can-
cer Centre in New York, studied 7535 men who had
radical prostatectomies and concluded approxi-
mately 250 similar procedures need to be per-
formed by the surgeon to increase the likelihood of
true elimination of cancer. An independent asso-
ciation with the cumulative total of surgeries was
identified by an increase in the PSA level, with an
average follow up of 50 months. These findings are
based on the work of 65 surgeons at four institu-
tions, over a time-span of 16 years. Dr Scardino
told the IJS: ‘‘The surgeons learning curve looks
like it continues to rise up to 250 procedures, but
the emphasis is actually on the principle that the
more the surgeon has done the better. This also
fits well with other studies that have looked at
complication rates and cancers of other organs.
There is probably a similar learning curve for
laparoscopic and robotic assisted laparoscopic
surgery.’’
2006 Prostate Cancer Symposium, San Francisco.
Blood pressure reduced by gastric
surgery
Research by Dr Fernstrom from the University of
Pittsburgh has revealed a significant reduction in
blood pressure in previously untreated hyperten-
sive patients who have had either a gastric by-pass
or vertical banded gastroplasty. 103 patients out of
a total of 347 were treated with blood pressure
drugs before surgery, 35 of which no longerrequired their medication post-surgery. This effect
was demonstrated in procedures performed from
1992 to 2001 and blood pressure remained low for
1.5 years after gastric surgery. Additional research
is necessary to determine if there is an eventual
reversion to presurgical blood pressure levels.
Fernstrom JD et al. Long-term changes in blood
pressure in extremely obese patients who have un-
dergone bariatric surgery. Arch Surg 2006;
141(3):276e283.
Infection rates higher in women
post-CABG
Women are significantly more likely than men to
harbour an infection at any site after a coronary
artery by-pass procedure according to research by
Dr Rogers at the University of Michigan, US. A 100-
day mortality rate of 9.4% in women compared to
6.4% in men, from 9218 patients (5749 men and
3469 women), over the age of 65. The infection
rate exhibited a similar trend over a year, as
women had a rate of 16.1% of compared to just
9.8% in men. Amongst those with infection, the
mortality rate within 100 days after surgery is
16.5% versus 6.2% amongst non-infected subjects.
Dr Rogers told the IJS: ‘‘The difference between
men and women is attributed to several factors
such as differences in blood sugar control among
diabetics, a higher prevalence of malnutrition
and the higher rate of immune related disorders
among women leading to the greater use of
immunosuppressants.’’
Rogers MA et al. Contribution of infection to in-
creased mortality in women after cardiac surgery.
Arch Intern Med 2006;166(4):437e443.
Melanoma vaccination strategy
One-third of melanoma patients may benefit from
a melanoma vaccination based on research by
Professor Herlyn at the Wistar Institute, Philadel-
phia. The mutated BRAF peptide known as BRAF
V600E is a suitable immunotherapeutic target
because of the high prevalence of its expression
and tumour specificity. This peptide is only
expressed intracellularly and is a good target for
T cells, with monocytes presenting the BRAF V600E
to killer T cells. 50% of melanoma patients have
killer T cells capable of recognizing the mutated
peptide, and this is an important premise for
developing the vaccine. Professor Herlyn told the
IJS: ‘‘A strong cancer-killing immune response is
100 Newsseen when killer T cells are stimulated with this
peptide. The results emphasize the potential of
this approach for creating an effective melanoma
vaccine, and we hope to move towards human
clinical trials as soon as possible.’’ Previous dis-
coveries at the Wistar Institute have initiated the
production of vaccinations for rabies, rubella and
the rotavirus.
Herlyn D et al. Human leukocyte antigen-
A2- restricted CTL responses to mutated BRAF




Novel stents for individuals with intracranial ath-
erosclerotic disease have been used by neurosur-
geons at Thomas Jefferson University Hospital,
Philadelphia. The self expanding stents are com-
posed of Nitinol, an alloy of titanium and nickel
rather than the steel used for coronary arterystents. The Wingspan Stent were inserted using
a minimally invasive technique developed by Pro-
fessor Rossenwar, who told the IJS: ‘‘It’s the first
self-expanding stent for intracranial use designed
specifically for atherosclerotic disease in the
brain. Up until recently all we could do was offer
anticoagulants such as Coumadin, Plavix and aspi-
rin to avoid a stroke. Other means such as balloon
angioplasty have a high complication rate of about
18e20%’’. Dr Veznedaroglu at the Jefferson Med-
ical College and the State University of New York,
is currently undertaking a prospective randomized
controlled trial involving the use of such stents in
patients who have had an acute stroke and
occlusion in a brain artery.
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